Carotid artery stenosis

Arterys Awarded Artificial Intelligence Solutions for Healthcare Agreement With Premier, Inc.

Retrieved on: 
Tuesday, November 15, 2022
Internet, SAN, Premier, Organization, AI, Patient Centered Primary Care Collaborative, Hospital, Health, Physician, Radiology, Entrepreneurship, FDA, Medical imaging, Carotid artery stenosis

SAN FRANCISCO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Arterys, developer of the world's first and market-leading internet platform for medical imaging, has been awarded a national group purchasing agreement for the Artificial Intelligence Solutions for Healthcare Category with Premier Inc.

Key Points: 
  • SAN FRANCISCO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Arterys, developer of the world's first and market-leading internet platform for medical imaging, has been awarded a national group purchasing agreement for the Artificial Intelligence Solutions for Healthcare Category with Premier Inc.
  • Effective Oct. 1, 2022, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Arterys' medical imaging platform and clinical AI workflow solutions.
  • Arterys offers radiology departments a dedicated medical imaging platform with a comprehensive set of clinical AI-enhanced workflow solutions - adding value across a wide range of specialties.
  • "We are excited to offer Premier's members access to the Arterys Medical Imaging AI Platform," says John Axerio-Cilies, CEO and Co-Founder of Arterys.

Low stroke risk in patients with very narrowed neck arteries

Retrieved on: 
Tuesday, May 24, 2022
Physician, Risk, Population, Blood, Kaiser Permanente, Patient, Health promotion, Carotid artery stenosis, Roger Hawkins (drummer), Stenosis, Health, Clinical trial, Stroke, Caregiver, Brain, Physical examination, Cholesterol, Division, Artery, Health education, Head, Face, Diagnosis, MD, District, Pharmaceutical industry, Medical imaging, Medical device, Research

OAKLAND, Calif. , May 24, 2022 /PRNewswire/ -- The risk of having a future stroke caused by a severe blockage in an artery in the neck that is not currently causing any symptoms is so low that most patients with this condition — asymptomatic carotid stenosis — could potentially be treated with the newest medications and may not require surgery, new Kaiser Permanente research suggests.

Key Points: 
  • Our analyses showed that this risk is so low that it appears that, for most patients, surgery may not be necessary."
  • The study, published May 24 in JAMA, is believed to be the largest and most current assessment of long-term stroke risk in this population.
  • Randomized clinical trials conducted prior to 2010 concluded that surgery to remove the blockage was the best option for reducing stroke risk in patients with severe stenosis.
  • But as medical treatments for reducing stroke risk have improved, physicians have begun to wonder whether surgery should remain the preferred treatment for asymptomatic patients.

Global Peripheral Embolic Protection Devices (Cardiovascular) Market Analysis and Forecast Report, 2015-2021 & 2022-2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 10, 2022
Health, Medical Devices, Cardiology, Region, Industry, Angioplasty, Renal artery stenosis, Plaque, EPD, Artery, Forecast model, Country, Carotid artery stenosis, Market access, Strategic planning, SWOT, COVID-19, CMO, Moyamoya disease, Pulmonary embolism, Review, Pharmaceutical industry, Weapon, Retail

The "Peripheral Embolic Protection Devices (Cardiovascular) - Global Market Analysis and Forecast Model" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Peripheral Embolic Protection Devices (Cardiovascular) - Global Market Analysis and Forecast Model" report has been added to ResearchAndMarkets.com's offering.
  • The model discusses in detail the impact of COVID-19 on Peripheral Embolic Protection Devices market for the year 2020 and beyond.
  • Currently marketed Peripheral Embolic Protection Devices market and evolving competitive landscape:
    Insightful review of the key industry trends.
  • Annualized total Peripheral Embolic Protection Devices market revenue by segment and market outlooks from 2015-2030.

Early Evaluation of Transcarotid Artery Revascularization (TCAR) Versus Carotid Endarterectomy (CEA) Cost-Effectiveness

Retrieved on: 
Monday, December 27, 2021
Incidence, Patient, JVS, TCAR, Stroke, MD, Death, CAS, University of California, San Diego Performance-Based Skills Assessment, University, CEA, Mortality, Quality of life, Journal, Quality-adjusted life year, Time, Carotid artery stenosis, ICER, Pharmaceutical industry

Carotid artery disease causes up to 20% of strokes.

Key Points: 
  • Carotid artery disease causes up to 20% of strokes.
  • Since its development in the 1950s, carotid endarterectomy has been the gold standard surgical therapy for the treatment of carotid disease.
  • With the advent of endovascular technology in the 1990s, carotid angioplasty and stenting (CAS) emerged as an alternative mode of revascularization.
  • The purpose of this study was to compare the quality of life, efficacy, and cost-effectiveness among patients undergoing TCAR versus CEA.

The innovative software "CAAS vFFR" by Pie Medical Imaging for the non-invasive physiological assessment of intermediate coronary lesions is the subject of FAST III, a multicenter European clinical trial which will investigate the effectiveness of the ve

Retrieved on: 
Thursday, December 9, 2021
PMI, Myocardial infarction, Angiography, Research, Adenosine, Medical imaging, CAAS, FFR, Patient, Method, Carotid artery stenosis, Erasmus MC, Roemheld syndrome, FAST, ECRI, Pharmaceutical industry

vFFR can assess whether a coronary artery narrowing is functionally severe and requires treatment.

Key Points: 
  • vFFR can assess whether a coronary artery narrowing is functionally severe and requires treatment.
  • CAAS vFFR allows doing so without the need of invasive wires- that are part of the routine practice to measure pressure gradients (FFR) and adenosine.
  • The trial is funded by research grants from Pie Medical Imaging (Maastricht, the Netherlands) and Siemens Healthineers GmbH (Erlangen, Germany).
  • PMI and 3mensio Medical Imaging are part of the Esaote Group, leader in the biomedical equipment sector.

The innovative software "CAAS vFFR" by Pie Medical Imaging for the non-invasive physiological assessment of intermediate coronary lesions is the subject of FAST III, a multicenter European clinical trial which will investigate the effectiveness of the ve

Retrieved on: 
Thursday, December 9, 2021
PMI, Myocardial infarction, Angiography, Research, Adenosine, Medical imaging, CAAS, FFR, Patient, Method, Carotid artery stenosis, Erasmus MC, Roemheld syndrome, FAST, ECRI, Pharmaceutical industry

vFFR can assess whether a coronary artery narrowing is functionally severe and requires treatment.

Key Points: 
  • vFFR can assess whether a coronary artery narrowing is functionally severe and requires treatment.
  • CAAS vFFR allows doing so without the need of invasive wires- that are part of the routine practice to measure pressure gradients (FFR) and adenosine.
  • The trial is funded by research grants from Pie Medical Imaging (Maastricht, the Netherlands) and Siemens Healthineers GmbH (Erlangen, Germany).
  • PMI and 3mensio Medical Imaging are part of the Esaote Group, leader in the biomedical equipment sector.

The Worldwide Neurovascular Devices Industry is Expected to Reach $3.4+ Billion by 2026 - ResearchAndMarkets.com

Retrieved on: 
Monday, September 6, 2021
Medical Devices, Health, Medicine, Medical terminology, Articles, Neurovascular bundle, Cerebrovascular disease, Stroke, Carotid artery stenosis, Disease

The demand for neurovascular devices is expected to surge due to the rise in the geriatric population, globally.

Key Points: 
  • The demand for neurovascular devices is expected to surge due to the rise in the geriatric population, globally.
  • The report also stated that the number of older people, worldwide, is expected to double to 1.5 million in the year 2050.
  • With the rise in neurological and neurovascular problems, the demand for neurovascular devices is expected to surge in the coming years.
  • These developments are expected to accelerate the demand for neurovascular devices in the region, in the coming years.

InspireMD Enrolls and Treats First Patients at Ballad Health System in U.S. Registration C-Guardian Clinical Trial of CGuard EPS

Retrieved on: 
Friday, July 23, 2021
Medical specialties, Medicine, Clinical medicine, Vascular diseases, Neurosurgery, Vascular surgery, Carotid stenting, Interventional radiology, Carotid artery stenosis, Stent, Restenosis, Angioplasty

The first patients, who were under the care of principal investigator, Chris Metzger, M.D., system chair of clinical research at Ballad Health System in Eastern Tennessee, were successfully implanted with the CGuard EPS stent device .

Key Points: 
  • The first patients, who were under the care of principal investigator, Chris Metzger, M.D., system chair of clinical research at Ballad Health System in Eastern Tennessee, were successfully implanted with the CGuard EPS stent device .
  • These are the first of 315 patients who are expected to be enrolled in the trial and treated with CGuard EPS in the treatment of carotid artery stenosis in symptomatic and asymptomatic patients undergoing carotid artery stenting.
  • I believe that the initiation of this trial marks an important milestone for the potential approval of CGuard EPS and the potential of CGuard EPS in advancing the treatment of CAD and stroke prevention, commented Dr. Metzger.
  • The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

The University of Sydney secured a AU$1.4M grant plus AU$2M from industry and partners with Allelica, Inc. to advance heart disease prevention strategies through Polygenic Risk Score application

Retrieved on: 
Monday, June 7, 2021
Circulatory system, Cardiovascular system, Cardiovascular diseases, Aging-associated diseases, Acute pain, Coronary artery disease, Medical emergencies, Cardiovascular disease, Polygenic score, Myocardial infarction, Preventive healthcare, Carotid artery stenosis

The University of Sydney has chosen to partner with Allelica to advance preventive healthcare strategies for coronary artery disease through the clinical application of polygenic risk score in risk assessment.

Key Points: 
  • The University of Sydney has chosen to partner with Allelica to advance preventive healthcare strategies for coronary artery disease through the clinical application of polygenic risk score in risk assessment.
  • The project is focused on improving heart disease prevention strategies through the application of Allelica's PRS in precision risk assessment.
  • Existing risk assessments for coronary artery disease focus on cholesterol levels and other risk factors such as smoking status, age and blood pressure.
  • Consequently, these patients are not prescribed the prevention strategies necessary to reduce the possibility of a heart attack or stroke.

InspireMD to Present at the LD Micro Virtual Invitational Conference on June 9, 2021

Retrieved on: 
Wednesday, June 2, 2021
Economy of New York City, NASDAQ, Carotid artery stenosis, Stroke, GlobeNewswire, Finance, Financial markets, Service companies

TEL AVIV, Israel, June 02, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq-CM: NSPR) developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by Carotid Artery Disease (CAD), announced today that Chief Executive Officer Marvin Slosman will present a corporate overview at the three-day LD Micro Virtual Invitational Conference being held on June 8 10, 2021.

Key Points: 
  • TEL AVIV, Israel, June 02, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq-CM: NSPR) developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by Carotid Artery Disease (CAD), announced today that Chief Executive Officer Marvin Slosman will present a corporate overview at the three-day LD Micro Virtual Invitational Conference being held on June 8 10, 2021.
  • Mr. Slosman will deliver his corporate presentation on June 9 at 11:30am ET, Track 3.
  • The Companys warrants, NSPR.WS and NSPR.WSB, currently traded on the NYSE: American, have been approved for listing on The Nasdaq Capital Market (Nasdaq).
  • Trading is expected to begin onJune 8, 2021, under the symbols NSPRW and NSPRZ on the Nasdaq.